Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.8
Journals
Current Oncology
Special Issues
Integrative and Multi-Modality Therapy in the Next Generation of Hepatocellular...
share announcement

Integrative and Multi-Modality Therapy in the Next Generation of Hepatocellular Carcinoma Management

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gastrointestinal Oncology".

Deadline for manuscript submissions: closed (31 October 2024) | Viewed by 2513

Special Issue Editors

Dr. Brandon M. Meyers

E-Mail Website
Guest Editor
Division of Medical Oncology, Juravinski Cancer Centre, McMaster University, 699 Concession St., Hamilton, ON L8V 5C2, Canada
Interests: hepatocellular carcinoma; real-world evidence; gastrointestinal oncology
Dr. Howard Lim

E-Mail Website
Guest Editor
British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada
Interests: hepatocellular carcinoma; GI oncology; genomics; health economics
Dr. Anand Swaminath

E-Mail Website
Guest Editor
Division of Radiation Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON L8V 5C2, Canada
Interests: radiation oncology; CNS malignancies; gastrointestinal malignancies
Dr. Pablo Emilio Serrano

E-Mail Website
Guest Editor
Department of Surgery, McMaster University, Hamilton, ON L8V 5C2, Canada
Interests: hepatobiliary surgical oncology

Special Issue Information

Dear Colleagues,

In the last few years, there has been a seismic shift in the available therapies for hepatocellular carcinoma (HCC). Multidisciplinary care encompasses surgical, interventional radiology, transplant, radiation and systemic therapy options, including the potential use of systemic therapies for HCC in the neo-adjuvant, adjuvant and advanced settings.

This Special Issue is looking for original manuscripts and reviews to explore all areas of treatment, including the following:

  1. Screening approaches;
  2. Cirrhosis management in the setting of HCC;
  3. Molecular classification, prognostic, and predictive biomarkers;
  4. New approaches in both interventional radiology, radiation, and surgical procedures;
  5. Approaches of neo-adjuvant strategies and adjuvant therapies;
  6. Multi-modality therapy in the advanced and metastatic setting;
  7. Therapy sequencing in early and advanced disease;
  8. Developments in immunotherapy and immunotherapy-based combinations.

We look forward to receiving your contributions.

Dr. Brandon M. Meyers
Dr. Howard Lim
Dr. Anand Swaminath
Dr. Pablo Emilio Serrano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatocellular carcinoma
  • HCC
  • multi-modality therapy
  • surgical therapy
  • interventional radiology
  • transplant
  • radiation therapy
  • systemic therapy
  • immunotherapy and immunotherapy-based combinations

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 739 KiB  
Article
Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment
by Rachel Gravell, Russell Frood, Anna Littlejohns, Nathalie Casanova, Rebecca Goody, Christine Podesta, Raneem Albazaz and Andrew Scarsbrook
Curr. Oncol. 2024, 31(10), 6384-6394; https://doi.org/10.3390/curroncol31100474 - 19 Oct 2024
Viewed by 811
Abstract
Background: The study purpose was to develop a machine learning (ML)-based predictive model for event-free survival (EFS) in patients with hepatocellular carcinoma (HCC) undergoing stereotactic ablative radiotherapy (SABR). Methods: Patients receiving SABR for HCC at a single institution, between 2017 and 2020, were [...] Read more.
Background: The study purpose was to develop a machine learning (ML)-based predictive model for event-free survival (EFS) in patients with hepatocellular carcinoma (HCC) undergoing stereotactic ablative radiotherapy (SABR). Methods: Patients receiving SABR for HCC at a single institution, between 2017 and 2020, were included in the study. They were split into training and test (85%:15%) cohorts. Events of interest were HCC recurrence or death. Three ML models were trained, the features were selected, and the hyperparameters were tuned. The performance was measured using Harrell’s C index with the best-performing model being tested on the unseen cohort. Results: Overall, 41 patients were included (training = 34, test = 7) and 64 lesions were analysed (training = 50, test = 14), resulting in 30 events (60% rate) in the training set (death = 6, recurrence = 24) and 8 events (57% rate) in the test set (death = 5, recurrence = 3). A Cox regression model, using age at treatment, albumin, and intra-lesional fat identified through MRI as variables, had the best performance with a mean training score of 0.78 (standard deviation (SD) 0.02), a mean validation of 0.78 (SD 0.18), and a test score of 0.94. Conclusions: Predicting the outcomes in patients with HCC, following SABR, using a novel model is feasible and warrants further evaluation. Full article
(This article belongs to the Special Issue Integrative and Multi-Modality Therapy in the Next Generation of Hepatocellular Carcinoma Management)
►▼ Show Figures

Figure 1

14 pages, 1033 KiB  
Article
Characteristics and Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Combination Therapy Who Achieved Complete Response
by Teiji Kuzuya, Naoto Kawabe, Hisanori Muto, Yoshihiko Tachi, Takeshi Ukai, Yuryo Wada, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Ryoji Miyahara and Yoshiki Hirooka
Curr. Oncol. 2024, 31(10), 6218-6231; https://doi.org/10.3390/curroncol31100463 - 16 Oct 2024
Viewed by 1086
Abstract
Aim: To investigate the characteristics and prognosis of patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (Atz/Bev) who achieved a complete response (CR) according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Methods: A total of 120 patients [...] Read more.
Aim: To investigate the characteristics and prognosis of patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (Atz/Bev) who achieved a complete response (CR) according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Methods: A total of 120 patients with Eastern Cooperative Oncology Group performance status (PS) 0 or 1 and Child–Pugh A at the start of Atz/Bev treatment were included. Barcelona Clinic Liver Cancer stage C was recorded in 59 patients. Results: The CR rate with Atz/Bev alone was 15.0%. The median time to CR was 3.4 months, and the median duration of CR was 15.6 months. A significant factor associated with achieving CR with Atz/Bev alone was an AFP ratio of 0.34 or less at 3 weeks. Adding transarterial chemoembolization (TACE) in the six patients who achieved a partial response increased the overall CR rate to 20%. Among the 24 patients who achieved CR, the median progression-free survival was 19.3 months, the median overall survival was not reached, and 14 patients (58.3%) were able to discontinue Atz/Bev and achieve a drug-free status. Twelve of these patients developed progressive disease (PD), but eleven successfully received post-PD treatments and responded well. Conclusions: Achieving CR by mRECIST using Atz/Bev alone or with additional TACE can be expected to offer an extremely favorable prognosis. Full article
(This article belongs to the Special Issue Integrative and Multi-Modality Therapy in the Next Generation of Hepatocellular Carcinoma Management)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop